Liina Haring1, Kati Koido2, Veiko Vasar3, Vambola Leping4, Kersti Zilmer5, Mihkel Zilmer6, Eero Vasar7. 1. Psychiatry Clinic of Tartu University Hospital, 31 Raja Street, Tartu 50417, Estonia. Electronic address: Liina.Haring@kliinikum.ee. 2. Institute of Biomedicine and Translational Medicine, University of Tartu, 19 Ravila Street, Tartu 50411, Estonia; Centre of Excellence for Translational Medicine, University of Tartu, 19 Ravila Street, Tartu 50411, Estonia. Electronic address: Kati.Koido@ut.ee. 3. Psychiatry Clinic of Tartu University Hospital, 31 Raja Street, Tartu 50417, Estonia. Electronic address: Veiko.Vasar@kliinikum.ee. 4. Institute of Computer Science, University of Tartu, 2 Liivi Street, Tartu 50409, Estonia. Electronic address: Vambola.Leping@ut.ee. 5. Institute of Biomedicine and Translational Medicine, University of Tartu, 19 Ravila Street, Tartu 50411, Estonia; Centre of Excellence for Translational Medicine, University of Tartu, 19 Ravila Street, Tartu 50411, Estonia. Electronic address: Kersti.Zilmer@ut.ee. 6. Institute of Biomedicine and Translational Medicine, University of Tartu, 19 Ravila Street, Tartu 50411, Estonia; Centre of Excellence for Translational Medicine, University of Tartu, 19 Ravila Street, Tartu 50411, Estonia. Electronic address: Mihkel.Zilmer@ut.ee. 7. Institute of Biomedicine and Translational Medicine, University of Tartu, 19 Ravila Street, Tartu 50411, Estonia; Centre of Excellence for Translational Medicine, University of Tartu, 19 Ravila Street, Tartu 50411, Estonia. Electronic address: Eero.Vasar@ut.ee.
Abstract
OBJECTIVE: The main goal of the present study was to analyze levels of cytokines of the interleukin family (IL-1α, IL-1β, IL-2, IL-4, IL-6, IL-8 and IL-10), interferon-gamma (IFN-γ), monocyte chemoattractant protein-1 (MCP1), tumor necrosis factor-alpha (TNF-α), and vascular endothelial and endothelial growth factors (VEGF and EGF), in the blood samples of first-episode psychosis (FEP) patients before and seven months after the start of antipsychotic medication use. METHOD: 38 anti-psychotic medication-naïve FEP patients and 37 healthy controls (HC) were recruited. Biochip array technology was used to measure cytokines and growth factors. RESULTS: The comparison of these markers in FEP patients and HC revealed significantly higher levels of EGF, IL-4 and IL-6 and significantly lower level of IL-1β in FEP patients before the antipsychotic treatment. Multiple regression analysis demonstrated significant correlations between FEP and EGF, IL-1β and smoking. Treatment with antipsychotic drugs resulted in a statistically significant amelioration of the symptoms of psychosis, but caused a significant increase in the body mass index (BMI) of patients. Levels of EGF, IL-2, VEGF, IL-6, IFN-γ, IL-4, IL-8 and IL-1α were significantly lower in treated FEP patients compared to premedication levels. CONCLUSIONS: According to the present study, EGF and IL-1β are markers of FEP. Antipsychotic drug treatment resulted in a significant clinical improvement of FEP patients and the suppression of positive symptoms was correlated with the decreased levels of EGF, IL-2 and IL-4. EGF was the strongest marker of FEP and treatment efficiency among the measured cytokines and growth factors.
OBJECTIVE: The main goal of the present study was to analyze levels of cytokines of the interleukin family (IL-1α, IL-1β, IL-2, IL-4, IL-6, IL-8 and IL-10), interferon-gamma (IFN-γ), monocyte chemoattractant protein-1 (MCP1), tumor necrosis factor-alpha (TNF-α), and vascular endothelial and endothelial growth factors (VEGF and EGF), in the blood samples of first-episode psychosis (FEP) patients before and seven months after the start of antipsychotic medication use. METHOD: 38 anti-psychotic medication-naïve FEP patients and 37 healthy controls (HC) were recruited. Biochip array technology was used to measure cytokines and growth factors. RESULTS: The comparison of these markers in FEP patients and HC revealed significantly higher levels of EGF, IL-4 and IL-6 and significantly lower level of IL-1β in FEP patients before the antipsychotic treatment. Multiple regression analysis demonstrated significant correlations between FEP and EGF, IL-1β and smoking. Treatment with antipsychotic drugs resulted in a statistically significant amelioration of the symptoms of psychosis, but caused a significant increase in the body mass index (BMI) of patients. Levels of EGF, IL-2, VEGF, IL-6, IFN-γ, IL-4, IL-8 and IL-1α were significantly lower in treated FEP patients compared to premedication levels. CONCLUSIONS: According to the present study, EGF and IL-1β are markers of FEP. Antipsychotic drug treatment resulted in a significant clinical improvement of FEP patients and the suppression of positive symptoms was correlated with the decreased levels of EGF, IL-2 and IL-4. EGF was the strongest marker of FEP and treatment efficiency among the measured cytokines and growth factors.
Authors: Liisa Leppik; Madis Parksepp; Sven Janno; Kati Koido; Liina Haring; Eero Vasar; Mihkel Zilmer Journal: Eur Arch Psychiatry Clin Neurosci Date: 2019-01-02 Impact factor: 5.270
Authors: Kärt Kriisa; Liina Haring; Eero Vasar; Kati Koido; Sven Janno; Veiko Vasar; Kersti Zilmer; Mihkel Zilmer Journal: Oxid Med Cell Longev Date: 2016-07-27 Impact factor: 6.543
Authors: Liisa Leppik; Kärt Kriisa; Kati Koido; Kadri Koch; Kärolin Kajalaid; Liina Haring; Eero Vasar; Mihkel Zilmer Journal: Front Psychiatry Date: 2018-04-24 Impact factor: 4.157